

Methyl aminolevulinate cream (Metvix[®])

(No. 51/03)

Galderma

Summary of Recommendation

10 November, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a resubmission

Accepted for restricted use within NHS Scotland

Methyl aminolevulinate cream (Metvix[®]) appears to be effective for the treatment of basal cell carcinoma in those patients in whom standard treatment with surgery or cryotherapy is contraindicated. Its use should be restricted to specialist dermatologists and to superficial lesions where penetration is most effective.

Professor David H Lawson
Chairman